ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Sequence mutations and gene amplifications lead to activation of the PIK3CA-AKT2 signaling pathway and have been reported in several types of neoplasms including ovarian cancer.
|
16721043 |
2006 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We also found that an activating (E545K) Pik3ca mutation, unlike Pten inactivation or Pik3ca H1047R mutation, cannot cooperate with Arid1a loss to promote ovarian cancer development in the mouse.
|
26279473 |
2016 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA gene encoding a catalytic subunit of the PI3K is mutated and/or amplified in various neoplasms, including ovarian cancer.
|
19029838 |
2009 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Interaction between PIK3CA rs3976507 and rs6443626 loci, and factors such as BMI, number of liveborn, tobacco, alcohol, and family history of ovarian cancer are associated with ovarian cancer risk.
|
31288947 |
2019 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
|
26909613 |
2016 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
PIK3CA mutations in ovarian cancer.
|
16203798 |
2005 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
|
27681437 |
2016 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Activation of the PI3K/mTOR pathway has been shown to be correlated with resistance to chemotherapy in ovarian cancer.
|
29371953 |
2017 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Likewise, the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is also a central regulator of the ovarian cancer.
|
29401696 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
These data suggested that PI3K induced epithelial-to-mesenchymal transition and promoted cell migration and invasion by activating the PI3K/AKT pathway in ovarian cancer.
|
30245957 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.
|
31284467 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we outline the importance of PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors in OC.
|
31128298 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The gene of phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) has been implicated as an oncogene in ovarian cancer [L. Shayesteh et al., Nat.Genet., 21: 99-102, 1999].
|
12874030 |
2003 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we show that dual inhibition of PI3K/mTOR in ovarian cancer-spheroids leads to death of inner matrix-deprived cells, whereas matrix-attached cells are resistant.
|
22340595 |
2012 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
We assayed a number of food phytochemicals with reported PI3K inhibitory ability to identify candidates that can influence CDDP treatment outcomes in chemoresistant OVCA cell lines.
|
24247248 |
2014 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.
|
30755818 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer.
|
29743815 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our in vivo data suggests that PIK3CA activation is one of the early genetic events in ovarian cancer.
|
19172191 |
2009 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
miR-214 targets the PTEN-mediated PI3K/Akt signaling pathway and regulates cell proliferation and apoptosis in ovarian cancer.
|
29113199 |
2017 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K/PKB signaling pathway in nude mice xenograft models of ovarian cancer.
|
27082164 |
2016 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
LHGDN |
Gain and/or amplification of PIK3CA gene, encoding the catalytic subunit of phosphatidylinositol 3-kinase (p110 alpha) and its increased expression are associated with enhanced PI3K activity in ovarian cancer cell lines.
|
17377809 |
2007 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The phosphatidylinositol 3-kinase (PI3K) pathway is one of the critical signaling cascades playing important roles in the chemoresistance of human cancer cells, including ovarian cancer.
|
23371322 |
2013 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Activation of the FOXM1 signaling pathway and the PI3K/AKT/mTOR signaling pathway is associated with poor prognosis in ovarian cancer.
|
30129654 |
2018 |